Clinical Trials Browser

Bronchiolitis Obliterans Syndrome, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Phase 1/2 Completed

53 enrolled 17 charts

LymphoidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT01221857 2021-08-03

Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

Phase 1/2 Completed

12 enrolled 9 charts

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02528682 2021-04-01

PSCT19

Phase 1/2 Completed

10 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT01474681 2020-12-30

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Phase 1/2 Completed

27 enrolled 15 charts

LymphoidMyeloidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT00526045 2020-12-17

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Phase 1/2 Completed

117 enrolled

BreastOther hematologic neoplasm

Breast Neoplasms, Hematologic Neoplasms

NCT01816230 2020-10-22

Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

Phase 1/2 Completed

36 enrolled 9 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03097770 2020-09-02

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Phase 1/2 Completed

100 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT01379209 2019-10-23

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Phase 1/2 Completed

68 enrolled

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02668315 2019-08-05

Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant

Phase 1/2 Completed

25 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT01460420 2017-07-06

EMN-alloRIC

Phase 1/2 Completed

49 enrolled

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00429416 2016-11-29

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Phase 1/2 Completed

14 enrolled 11 charts

Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

NCT00673114 2015-04-03

Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

Phase 1/2 Completed

3 enrolled 12 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT00809276 2015-02-16

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Phase 1/2 Completed

92 enrolled 5 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00423124 2014-05-30

Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies

Phase 1/2 Completed

57 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT00202917 2014-05-29

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

Phase 1/2 Completed

61 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT00379587 2014-03-19

Rituximab for Prevention of Chronic GVHD

Phase 1/2 Completed

65 enrolled 9 charts

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT00750815 2014-01-20

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

Phase 1/2 Completed

58 enrolled 11 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00405743 2013-09-18

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Phase 1/2 Completed

153 enrolled

Other hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Hematologic Neoplasms

NCT00369226 2013-07-25

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Phase 1/2 Completed

45 enrolled 12 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT00993486 2013-06-20

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Phase 1/2 Completed

19 enrolled

Other hematologic neoplasm

Graft vs Host Disease, Hematologic Diseases, Hematologic Neoplasms

NCT01732393 2012-12-05

Effect of Quercetin in Prevention and Treatment of Oral Mucositis

Phase 1/2 Completed

20 enrolled

OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT00056966 2012-06-29

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Phase 1/2 Completed

24 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00881946 2012-04-04

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Phase 1/2 Completed

73 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00312429 2012-04-03

Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer

Phase 1/2 Completed

34 enrolled

Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT00506857 2012-02-28

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

Phase 1/2 Completed

82 enrolled 6 charts

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT00987987 2011-01-24

ILD-Treg

Phase 1/2 Completed

21 enrolled

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT00689000 2010-10-22

Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Phase 1/2 Completed

57 enrolled

MyeloidOther hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Clinical Trials

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

Reduced Intensity Haploidentical Transplant for Hematological Malignancies

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Compassionate Use Study of Tenalisib (RP6530)

Dose-range Finding Treosulfan-based Conditioning

Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

PSCT19

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant

EMN-alloRIC

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

Rituximab for Prevention of Chronic GVHD

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Effect of Quercetin in Prevention and Treatment of Oral Mucositis

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

ILD-Treg

Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)